OZASA HIROAKI

Profile Information

Affiliation: Kyoto University

Degree: 医学博士

J-GLOBAL ID: 201101025890663213
researchmap Member ID: 6000028359

Research Areas

Life sciences / Tumor diagnostics and therapeutics / 肺癌、治療初期生存、獲得耐性、転移性腫瘍、腫瘍微小環境、一塩基多型

Research History

Apr, 2023 - Present

肺癌診療ユニット長, がん診療部, 京都大学医学部附属病院
Oct, 2021 - Present

病院講師, 呼吸器内科学, 京都大学大学院医学研究科
Apr, 2015 - Sep, 2021

助教, 呼吸器内科学, 京都大学大学院医学研究科
Jan, 2013 - Mar, 2015

特定病院助教, 集学的がん診療学講座, 京都大学大学院医学研究科
Nov, 2012 - Dec, 2012

医員, 呼吸器内科学, 京都大学大学院医学研究科
Apr, 2011 - Oct, 2012

助教, 腫瘍・免疫内科学, 名古屋市立大学大学院医学研究科
Apr, 2006 - Mar, 2011

Assistant Professor, Nagoya City University Graduate School of Medical Sciences, Department of Medical Oncology and Immunology, Graduate School of Medical Sciences
Mar, 2004 - Mar, 2006

医員, 呼吸器内科, 岐阜県立多治見病院
May, 2002 - Feb, 2004

研修医, 第2内科, 名古屋市立大学病院

Education

- Mar, 2002

Medical Sciences, Nagoya City University
Apr, 2006 - Mar, 2010

Nagoya City University

Committee Memberships

Dec, 2016 - Present

評議員, 日本肺癌学会
Apr, 2022 - Present

地域連携部会, 京都府がん医療戦略推進会議
Jan, 2024 - Present

倫理委員会, 日本肺癌学会

Major Papers

Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer

Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo …

Molecular Cancer Therapeutics, Dec 6, 2023 Peer-reviewedCorresponding author
CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

Tatsuya Ogimoto, Hiroaki Ozasa, Hironori Yoshida, Takashi Nomizo, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Hitomi Ajimizu …

Oncology Letters, 26(2), Jul 10, 2023 Peer-reviewedCorresponding author
Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe …

Scientific reports, 13(1) 2117-2117, Feb 6, 2023 Peer-reviewed
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.

Masatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Tatsuya Ogimoto, Hitomi Ajimizu, Hironori Yoshida …

Cancer science, 114(2) 546-560, Feb, 2023 Peer-reviewedCorresponding author
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.

Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna …

Science translational medicine, 14(675) eabq0021, Dec 14, 2022 Peer-reviewed
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.

Kentaro Hashimoto, Hiroaki Ozasa, Akihiko Yoshizawa, Hiroshi Yoshida, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Funazo, Hironori Yoshida …

Oncology letters, 24(5) 402-402, Nov, 2022 Corresponding author
Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.

Shunichi Nagata, Masatsugu Hamaji, Hiroaki Ozasa, Yoshito Yamada, Akihiro Ohsumi, Hiroshi Date

Clinical lung cancer, 23(5) e321-e324, Jul, 2022 Peer-reviewed
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

Hitomi Ajimizu, Hiroaki Ozasa, Susumu Sato, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, Kiyomitsu Kuninaga, Tatsuya Ogimoto, Kazutaka Hosoya, Masatoshi Yamazoe …

Scientific reports, 11(1) 23677-23677, Dec 8, 2021 Peer-reviewed
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.

Hironori Yoshida, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hitomi Ajimizu, Masatoshi Yamazoe, Kiyomitsu Kuninaga, Tatsuya Ogimoto …

European journal of cancer (Oxford, England : 1990), 144 317-325, Feb, 2021 Peer-reviewedCorresponding author
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.

Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori …

Molecular cancer therapeutics, 19(6) 1320-1327, Jun, 2020 Peer-reviewedCorresponding author
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression.

Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori …

Cell death & disease, 11(3) 177-177, Mar 9, 2020 Peer-reviewedCorresponding author
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.

Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami …

JCI insight, 5(2), Jan 30, 2020 Peer-reviewed
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.

Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda …

Nature communications, 11(1) 74-74, Jan 3, 2020 Peer-reviewedCorresponding author
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.

Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim

Scientific reports, 9(1) 17085-17085, Nov 19, 2019 Peer-reviewedCorresponding author
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda …

Molecular cancer research : MCR, 17(1) 212-224, Jan, 2019 Peer-reviewedCorresponding author
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai …

Oncotarget, 8(42) 71805-71816, Sep 22, 2017 Peer-reviewedCorresponding author
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai …

Scientific reports, 7(7) 45124-45124, Mar 23, 2017 Peer-reviewedCorresponding author
Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells.

Hiroaki Ozasa, Tetsuya Oguri, Ken Maeno, Osamu Takakuwa, Eiji Kunii, Yoshitaka Yagi, Takehiro Uemura, Daishi Kasai, Mikinori Miyazaki, Akio Niimi

Cancer science, 105(8) 1032-9, Aug, 2014 Peer-reviewedLead author
Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

Daishi Kasai, Hiroaki Ozasa, Tetsuya Oguri, Mikinori Miyazaki, Takehiro Uemura, Osamu Takakuwa, Eiji Kunii, Hirotsugu Ohkubo, Ken Maeno, Akio Niimi

Anticancer research, 33(5) 1935-40, May, 2013 Peer-reviewed
Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.

Hiroaki Ozasa, Tetsuya Oguri, Takehiro Uemura, Mikinori Miyazaki, Ken Maeno, Shigeki Sato, Ryuzo Ueda

Cancer science, 101(1) 161-6, Jan, 2010 Peer-reviewedLead author

Misc.

124

Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

Masatoshi Yamazoe, Hiroaki Ozasa, Tetsuya Ohgimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Funazo, Yuto Yasuda, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani …

CANCER RESEARCH, 81(13), Jul, 2021 Corresponding author
Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

Masatoshi Yamazoe, Hiroaki Ozasa, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori …

CANCER SCIENCE, 112 890-890, Feb, 2021 Corresponding author
YAP1は抗Apoptosis因子Mcl-1とBcl-xLの発現調節を介して,ALK陽性肺癌細胞の初期生存を仲介する

辻貴宏, 小笹裕晃, 青木航, 油屋駿介, 船造智子, 山添正敏, 味水瞳, 安田有斗, 野溝岳, 吉田博徳 …

日本肺癌学会学術集会号, 61st, 2020 Corresponding author
Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer.

Hironori Yoshida, Hiroki Nagai, Yuichi Sakamori, Hiroaki Ozasa, Takashi Nishimura, Keisuke Tomii, Toyohiro Hirai, Yukinori Matsuo, Yusuke Iizuka, Takashi Mizowaki …

In vivo (Athens, Greece), 34(2) 897-902, 2020
非小細胞肺癌初回治療における化学療法+免疫チェックポイント阻害剤併用療法の多施設共同後ろ向き観察研究.

吉田博徳、金永学、岩坪重彰、小笹裕晃、阪森優一、平井豊博、西村尚志、坂口才、野口哲男、三尾直士

第60回日本肺癌学会学術集会. 大阪, Dec 6, 2019
Efficacy of MCL1 inhibitor S63845 in small cell lung cancer in vitro and in vivo.

Yasuda Y, Ozasa H, Tsuji T, Nomizo T, Funazo T, Ajimizu H, Yamazoe M, Yoshida H, Sakamori Y, Hirai T, and Kim YH

第78回日本癌学会学術総会京都, Sep 26, 2019 Corresponding author
転移性脳腫瘍の可視化モデル

辻貴宏、和氣弘明、小笹裕晃、進藤麻理子、味水瞳、山添正敏、安田有斗、阪森優一、野溝岳、金永学、平井豊博

第78回日本癌学会学術総会, Sep 26, 2019
ロルラチニブが投与されたALK陽性肺癌4例の検討.

住永圭一郎、吉田博徳、阪森優一、小笹裕晃、平井豊博、金永学

第110回日本肺癌学会関西支部学術集会., Jun 29, 2019
ABCC11 is involved in resistance to alectinib

Tomoko Yamamoto Funazo, Hiroaki Ozasa, Takahiro Tsuji, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida …

AACR Annual Meeting 2019, April 1, 2019, Apr, 2019 Peer-reviewedCorresponding author
Association of ALDH7A1 overexpression with chemotherapy resistance and cancer stem cell in lung cancer

Yuto Yasuda, Yuichi Sakamori, Hiroaki Ozasa, Hitomi Ajimizu, Tetsuya Oguri, Ken Maeno, Takahiro Tsuji, Takashi Nomizo, Tomoko Yamamoto, Hironori Yoshida …

AACR Annual Meeting 2019, April 1, 2019, Apr, 2019 Peer-reviewed
Real-time visualization of brain metastasis in vivo

Takahiro Tsuji, Hiroaki Wake, Hiroaki Ozasa, Koichiro Haruwaka, Hitomi Ajimizu, Yuto Yasuda, Yuichi Sakamori, Takashi Nomizo, Young Hak Kim, Toyohiro Hirai

AACR Annual Meeting 2019, April 1, 2019, Apr, 2019 Peer-reviewed
In vitro and in vivo efficacy of MCL1 inhibitor S63845 in small cell lung cancer

Yuto Yasuda, Hiroaki Ozasa, Takahiro Tsuji, Takashi Nomizo, Tomoko Yamamoto, Hitomi Ajimizu, Hironori Yoshida, Yuichi Sakamori, Toyohiro Hirai, Young Hak Kim

AACR Annual Meeting 2019, April 1, 2019, Apr, 2019 Peer-reviewedCorresponding author
YAP1 mediates initial survival of alectinib therapy in ALK-rearranged lung cancer via pro-apoptotic protein regulation

Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo …

AACR Annual Meeting 2019, March 31, 2019, Mar, 2019 Peer-reviewedCorresponding author
ドライバー変異陰性の非小細胞肺癌に対する2次治療としてのニボルマブとその他の抗癌剤との比較検討

阪森優一, 味水瞳, 山本智子, 安田有斗, 野溝岳, 辻貴宏, 吉田博徳, 小笹裕晃, 金永学

第59回日本肺癌学会学術集会., 2018.11.30. 東京, Nov, 2018 Peer-reviewed
Nivolumabに耐性を来たした非小細胞肺癌の臨床的特徴の検討

吉田博徳, 味水瞳, 山本智子, 安田有斗, 野溝岳, 辻貴宏, 阪森優一, 小笹裕晃, 平井豊博, 金永学

第59回日本肺癌学会学術集会., 2018.11.30. 東京, Nov, 2018 Peer-reviewed
Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab.

Yamamoto T, Ozasa H, Nomizo T, Ajimizu H, Yasuda Y, Tsuji T, Yoshida H, Nagai H, Sakamori Y, Hirai T …

ESMO 2018 Congress., 2018.10.20. Munich, Germany, Oct, 2018 Peer-reviewedCorresponding author
PD-L1 rs2282055 genotypes are oppositely associated with response to platinum-based chemotherapy and nivolumab treatmen

Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Sakamori Y, Hirai T, Kim YH

第77回日本癌学会学術総会, 2018.9.27. 大阪, Sep, 2018 Peer-reviewedCorresponding author
Efficacy of MCL1 inhibitor S63845 in small cell lung cancer.

Yasuda Y, Ozasa H, Tsuji T, Nomizo T, Funazo T, Ajimizu H, Yoshida H, Sakamori Y, Hirai T, Kim YH

第77回日本癌学会学術総会, 2018.9.27. 大阪, Sep, 2018
ペムブロリズマブ無効でクリゾチニブが著効したPD-L1高発現・ROS1陽性肺癌の一例.

丸口直人, 吉田博徳, 阪森優一, 小笹裕晃, 平井豊博, 金永学

第108回日本肺癌学会関西支部学術集会, 2018.6.30. 大阪, Jun, 2018 Peer-reviewed
PD-L1 rs2282055 is associated with opposite treatment effect between platinum-based chemotherapy and nivolumab treatment

Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Sakamori Y, Hirai T, Kim YH

AACR Annual Meeting 2018., 2018.4.16. Chicago, USA, Apr, 2018 Peer-reviewed

Books and Other Publications

最新呼吸器内科・外科学

小笹裕晃 (Role: Joint author, 総論：腫瘍マーカー、喀痰検査各論：進行肺癌の治療（細胞障害性抗がん剤、分子標的治療）)

株式会社メディカルレビュー, Oct 30, 2019
中山書店内科学書改訂第９版

辻貴宏、小笹裕晃 (Role: Joint author, 悪性腫瘍の薬物治療・放射線治療)

中山書店, Aug, 2019
呼吸と循環

小笹裕晃, 佐藤晋 (Role: Contributor, 肺癌診療専門内科医からみたCOPD)

医学書院, Aug, 2016

Presentations

肺がんにおける適切なICI治療選択は？～最新知見からKEYNOTE-189、407を振り返る～

小笹裕晃

Lung Cancer Clinical Seminar in TOKAI, Feb 22, 2024 Invited
肺がんにおける適切なICI治療選択は？～最新知見からKEYNOTE-189、407を振り返る～

小笹裕晃

Lung Cancer Clinical Seminar 2024 ~肺癌診療の実態に迫る～京都, Jan 30, 2024 Invited
胸部悪性腫瘍におけるCGP検査の実施意義

小笹裕晃

Tochigi expert Genome Seminar on Lung Cancer 栃木, Jan 25, 2024 Invited
ALK・ROS1融合遺伝子肺癌の最適な治療方針を考える～肺癌におけるゲノムプロファイリングの必要性を踏まえて～

小笹裕晃

第102回日本呼吸器学会近畿地方会・第7回日本呼吸器ケア・リハビリテーション学会近畿支部学術集会合同学会ランチョンセミナー４, Jan 20, 2024 Invited
胸部悪性腫瘍におけるCGP検査の実施意義

小笹裕晃

若手医師のための肺癌勉強会 in 神戸, Dec 21, 2023 Invited
肺がんにおける免疫チェックポイント阻害薬の位置づけ

小笹裕晃

膠原病 irAE を考える会 in 京都, Nov 9, 2023 Invited
マルチ遺伝子検査と希少肺がんにおける薬物療法～BRAF,MET 阻害薬を中心に～

小笹裕晃

Lung Cancer Hands on Seminar in Kyoto, Oct 28, 2023 Invited
ALK陽性肺癌の１次治療におけるロルラチニブの果たすべき役割とは？

小笹裕晃

Lung Cancer Internet Symposium, Oct 5, 2023 Invited
肺がんにおける適切なICI治療選択は？～最新知見からKEYNOTE-189,407を振り返る～

小笹裕晃

Lung Cancer Clinical Seminar 2023~肺癌診療の実際に迫る~, Sep 29, 2023 Invited
ALK陽性肺癌の１次治療におけるロルラチニブの果たすべき役割とは？～最新のフォローアップデータを交えて～

小笹裕晃

第118回日本肺癌学会関西支部学術集会学術セミナー, Jun 17, 2023 Invited
胸部悪性腫瘍におけるCGP検査の実施意義

桜山肺がんゲノム適正使用・連携を考える会, May 26, 2023 Invited
肺癌におけるCGP検査の活用を考える！

CGP Expert Board Web Seminar -On Lung Cancer-, May 15, 2023 Invited
肺癌転移性脳腫瘍の生体内観察モデルを用いた新規治療薬の検討

第63回日本呼吸器学会学術講演会、日本呼吸器財団研究助成成果報告, Apr 29, 2023 Invited
ALK陽性肺癌の治療戦略を考える～基礎から臨床まで～

小笹裕晃

Lung Cancer Seminar, Feb 10, 2023 Invited
希少肺癌の診断と治療～実臨床におけるALK陽性肺癌を中心に～

小笹裕晃

京滋希少肺癌講演会2022, Mar 22, 2022 Invited
「ALK陽性肺癌の最適治療を考える～アレクチニブの位置づけ～」

小笹裕晃

第98回日本呼吸器学会近畿地方会、ランチョンセミナー, Dec 11, 2021 Invited
当院におけるマルチコンパニオン診断を用いた最適化治療について ~実臨床の経験を中心に~

小笹裕晃

Lung Cancer Precision Medicine Web Seminar, Aug 26, 2021 Invited
「当院におけるNGSマルチCDx用の検体採取について」

小笹裕晃

第113回日本肺癌学会関西支部学術集会ランチョンセミナー, Feb 27, 2021 Invited
COPD合併肺癌の予後

小笹裕晃

第89回閉塞性肺疾患研究会ミニシンポジウム, Jul 18, 2015 Invited

Professional Memberships

Research Projects

肺癌転移性肝腫瘍における肝転移生体内観察モデルを用いた新規治療戦略の開発

科学研究費助成事業基盤研究(C), 日本学術振興会, Apr, 2023 - Mar, 2026

吉田博徳小笹裕晃
肺癌転移性脳腫瘍の生体内観察モデルを用いた、新規治療薬の検討

日本呼吸器財団, Nov, 2020 - Apr, 2023

小笹裕晃
脳内微小環境と癌細胞の相互作用を解明する異分野融合的解析法

次世代がん医療加速化研究事業, Apr, 2021 - Mar, 2023

辻貴宏小笹裕晃
Development of new therapeutic strategies for driver mutation-positive lung cancer

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2022

Ozasa Hiroaki
Application of iPS cell technology to lung regeneration and development of bioresource for elucidating the mechanisms of lung diseases

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), Japan Society for the Promotion of Science, Apr, 2015 - Mar, 2018

Michiaki Mishima
Clinical and therapeutic implications of nestin in small cell lung cancer

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2014 - Mar, 2018

Maeno Ken

Profile Information

Research Areas

Research History

Education

Committee Memberships

Major Papers

Misc.

Books and Other Publications

Presentations

Professional Memberships

Research Projects

Menu

Coauthors